Lilly's Zepbound Tops Wegovy for Weight Loss in Trial
Favicon 
www.newsmax.com

Lilly's Zepbound Tops Wegovy for Weight Loss in Trial

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines. In the 751-person trial, Zepbound helped patients lose...